文献速递淋巴瘤

血浆甲基化DNA标志物检测淋巴瘤:发现、验证与临床先导试验

Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot.
PubMed 文献 · Am J Hematol · 2024-11-20

研究通过对冷冻组织进行简化代表性亚硫酸氢盐测序发现淋巴瘤甲基化DNA标志物,在独立FFPE组织中验证后开发16项TELQAS检测,并在初治淋巴瘤患者与健康对照血浆中测试;在90%特异性下检出78%(95%CI,74%-82%)淋巴瘤病例,排除边缘区及T细胞淋巴瘤后敏感性升至84%(80%-88%)。

要点

  • 16项血浆甲基化DNA标志物检测在90%特异性下检出78%淋巴瘤病例。
  • 排除边缘区及T细胞淋巴瘤后敏感性升至84%。
  • 血浆甲基化DNA标志物有望用于淋巴瘤检测及多癌种检测研究。

核心结论

  • 血浆甲基化DNA标志物在检测淋巴瘤方面显示出前景,可作为多癌种检测研究的候选标志物。

研究设计与样本

  • 对冷冻组织发现集进行简化代表性亚硫酸氢盐测序(RRBS),将识别的甲基化DNA标志物转化为甲基化特异性PCR并在独立FFPE组织中验证。
  • 开发靶向富集长探针定量放大信号(TELQAS)检测,在独立初治淋巴瘤患者与健康对照的血浆提取、亚硫酸氢盐转化DNA中测定。
  • 使用随机森林模型结合计算机交叉验证预测癌症状态。

主要发现

  • 16项TELQAS检测(ZNF503、VWA5B1、HOXA9、GABRG3、ITGA5、MAX.chr17.7190、BNC1、CDK20、MAX.chr4.4069、TPBG、DNAH14、SYT6、CACNG8、FAM110B、ADRA1D和NRN1)在90%特异性下检出78%(95%CI,74%-82%)的淋巴瘤病例。
  • 排除边缘区淋巴瘤和T细胞淋巴瘤后,敏感性增至84%(80%-88%)。

关键数值与推荐

  • 16项血浆TELQAS检测在90%特异性下检出78%(95%CI,74%-82%)淋巴瘤病例。
  • 排除边缘区及T细胞淋巴瘤后敏感性为84%(95%CI,80%-88%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lymphoma is one of the leading causes of cancer and cancer deaths and yet has not been amenable to population screening. The role of methylated DNA markers (MDMs) in the detection of lymphoma has not been extensively studied. We aimed to discover, validate, and test tissue-derived MDMs of lymphoma in archival plasma specimens. Reduced representation bisulfite sequencing (RRBS) was performed on a discovery set of frozen tissues. MDMs identified were converted to methylation-specific PCR assays and validated on independent formalin-fixed, paraffin-embedded (FFPE) tissues. Target enrichment long-probe quantitative-amplified signal (TELQAS) assays were developed and assayed in plasma-extracted, bisulfite-converted DNA from independent treatment-naïve lymphoma patients and healthy controls. Prediction of cancer status was modeled using random forest model with in silico cross-validation. After discovery and validation in tissue, 16 TELQAS assays (ZNF503, VWA5B1, HOXA9, GABRG3, ITGA5, MAX.chr17.7190, BNC1, CDK20, MAX.chr4.4069, TPBG, DNAH14, SYT6, CACNG8, FAM110B, ADRA1D, and NRN1) were selected for testing in plasma. These detected 78% (95% CI, 74%-82%) of lymphoma cases at 90% specificity. Excluding marginal zone and T-cell lymphomas, sensitivity increased to 84% (80%-88%). MDMs in plasma show promise to detect lymphoma and are candidates for inclusion in multi-cancer detection studies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Witzig TE, Taylor WR, Mahoney DW, et al. Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot. Am J Hematol. 2024. PMID: 39564730. doi:10.1002/ajh.27533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。